Special Issue "Ubiquitin and Ubiquitin-Like Proteins: From Basic Mechanisms to Human Disorders"
Deadline for manuscript submissions: closed (31 October 2020) | Viewed by 15055
Interests: muscle atrophy; cachexia; ubiquitin; ubiquitinating enzymes; proteasome
Eukaryotic proteins can be modified by a variety of post-translational modifications (PTM) such as phosphorylation, acetylation, methylation, etc. Among these, ubiquitination is a widespread PTM and corresponds to the transient attachment of ubiquitin (UB), a small protein (8.6 kDa) conserved among the Eukaryota. Since three decades, other protein modifiers, called ubiquitin-like proteins (UBL), have been identified, presenting significant sequence similarity to ubiquitin (e.g., SUMO, NEDD8, ISG15, FAT10, etc.). UB and UBL are attached to proteins by similar enzymatic cascades and form multiple types of monomeric or polymeric-chain PTM. These different types of PTM determine the fate of a protein (protein degradation, localization, interactions, and activity). UB and some UBL marks can be further modified by additional post-translational modifications, such as phosphorylation, or reversed (e.g., by deubiquitinases, DUBs). UB and UBL regulate many cellular processes, and, not surprisingly, dysregulation of this system (e.g., mutations in the enzymatic cascade or DUBs) is associated with many pathologies. This Special Issue aims to identify and review the latest advances in the field and illustrate the therapeutic prospects of targeting the ubiquitinating and deubiquitinating enzymes in human diseases.
Dr. Cécile Polge
Dr. Alfred Vertegaal
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2300 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Ubiquitin-like proteins
- Ubiquitinating enzymes (E1, E2, E3)
- Deubitinases (DUBs)
- Human pathologies